



## Sunday, December 4, 2016

**10:30 - 11:45: Press Conference (PR01)**

Room: Schubert 1

**Chairs:** Robert Pirker, Medical University of Vienna, Austria & Giorgio Scagliotti, University of Turin, Italy

- **PR01.01: Welcome** - Robert Pirker, Medical University of Vienna, Austria & Giorgio Scagliotti, University of Turin, Italy
- **PR01.02: Shared Decision Making (SDM) and Patient Decision Aids (PDAs) in Lung Cancer: Survey of Patients, Significant Others or Caregivers** - Laurie Gaspar, University of Colorado, USA
- **PR01.03: The ALCF Centers of Excellence Model Delivers a Standard of Care to the Community Similar to Academic and Research Centers** - Raymond Osarogiagbon, Baptist Cancer Center, USA
- **PR01.04: Mesothelioma Workshop**
- **PR01.05: E-health and Future Technologies in Evidence Based Nursing Care** - Roma Maguire, University of Surrey, UK
- **PR01.06: Honored Guest**



## Monday, December 5, 2016

**10:30 - 11:45: Press Conference (PR02): Active Prevention**

Room: Schubert 1

Chair: Carolyn Dresler, President of the Human Rights and Tobacco Control Network, USA

- **PR02.01: Implementing Tobacco Control Measures in Uruguay** - Tabaré Vázquez, President of Uruguay, Uruguay
- **PR02.02: Framework Convention on Tobacco Control: Its impact on Global Health** - Vera da Costa e Silva, WHO Framework Convention on Tobacco Control, Switzerland
- **PR02.03: Free Trade & Investment Agreement Threatens Public Health** - Zariah Zain, Lincoln University College Malaysia, Malaysia
- **PR02.04: Tobacco Control** - Luke Clancy, TobaccoFree Research Institute Ireland, Ireland
- **PR02.05: Tobacco-free Investments and Portfolios** - Bronwyn King, Tobacco Free Portfolios, Australia



## Tuesday, December 6, 2016

**10:30 - 11:45: Press Conference (PR03): Accurate Diagnosis**

Room: Schubert 1

Chair: Tony Mok, The Chinese University of Hong Kong, Hong Kong

- **PR03.03: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)** - Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China
- **PR03.01: Lung Cancer Staging - Changing the Clinical Practice** - Ramon Rami-Porta, Hospital Universitari Mutua Terrassa, and CIBERES Lung Cancer Group, Spain
- **PR03.02: Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)** - Vassiliki Papadimitrakopoulou, MD Anderson Cancer Center, USA
- **PR03.04: First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)** - Gilberto De Castro Jr, Instituto do Câncer do Estado de São Paulo - ICESP, Brazil



## Wednesday, December 7, 2016

10:30 - 11:45: Press Conference (PR04): Advanced Care

Room: Schubert 1

Chair: Christoph Zielinski, Medical University of Vienna, Austria

- **PR04.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS  $\geq$ 50%: Data from KEYNOTE-024** - Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA
- **PR04.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses** - Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA
- **PR04.03: Durvalumab in  $\geq$ 3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study** - Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
- **PR04.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC** - Julien Adam, Gustave Roussy Cancer Campus, France
- **PR04.05: A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): With Translational Research (TR) Biopies** - Paul Baas, Netherlands Cancer Institute, Netherlands